Gastrointestinal manifestations of systemic sclerosis

Journal of Scleroderma and Related Disorders

Volumn 1, Issue 3, 2016, Pages 247-256

  Shreiner, Andrew B ^a   Murray, Charles ^b   Denton, Christopher ^b   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gastrointestinal; Motility; Scleroderma; Systemic sclerosis

Indexed keywords

BACLOFEN; BISACODYL; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; LINACLOTIDE; MACROGOL; METOCLOPRAMIDE; METRONIDAZOLE; NEOSTIGMINE; OCTREOTIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; PRUCALOPRIDE; RANITIDINE; RIFAXIMIN;

ASPIRATION; BACTERIAL OVERGROWTH; CONSTIPATION; DIARRHEA; ENDOSCOPY; ESOPHAGUS MANOMETRY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL OBSTRUCTION; HELICOBACTER INFECTION; HUMAN; IMMUNE SYSTEM; INTESTINE INFECTION; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALNUTRITION; MORBIDITY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SCLERODERMA; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH PARESIS; SYSTEMIC SCLEROSIS;

EID: 85031703677     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.5301/jsrd.5000214     Document Type: Review

References (86)

1. Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford). 2010;49(9):1770-1775.
2. Sandmeier B, Jäger VK, Nagy G, et al. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clin Exp Rheumatol. 2015;33(4)(Suppl 91):S75-S79.
3. Schmeiser T, Saar P, Jin D, et al. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int. 2012;32(8):2471-2478.
4. Bodukam V, Hays RD, Maranian P, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford). 2011;50(2): 330-334.
5. Omair MA, Lee P. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis. J Rheumatol. 2012;39(5):992-996.
6. Manetti M, Neumann E, Milia AF, et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum. 2007;56(10): 3442-3447.
7. Papachristos DA, Nikpour M, Hair C, Stevens WM. Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis. Intern Med J. 2015;45(10):1077-1081.
8. Manetti M, Neumann E, Müller A, et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum. 2008;58(9):2866-2873.
9. Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016;55(1):115-119.
10. Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X, Denton CP. Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology (Oxford). 2012; 51(11):1989-1998.
11. Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol. 2012;107(4):597-603.
12. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428-440.
13. Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972;58(1):30-44.
14. Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015;15(1):24.
15. Lepri G, Guiducci S, Bellando-Randone S, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis. 2015;74(1):124-128.
16. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford). 2013;52(6):1095-1100.
17. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol. 1991;31(6): 683-687.
18. Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21(1):43-45.
19. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
20. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691-712.
21. Pakozdi A, Wilson H, Black CM, Denton CP. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol. 2009;27(3)(Suppl 54):5-8.
22. Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2016 May 13. pii: kew216.
23. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10(6):e0128004.
24. Gordon D, Young LR, Reddy S, Bergman C, Young JD. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. J Hosp Infect. 2016;92(2):173-177.
25. Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc. 2015;4(11): e002245.
26. Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int. 2016;27(6):2117-2126.
27. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016; 176(2):238-246.
28. Gomm W, von Holt K, Thomé F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-416.
29. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241-249.
30. Hershcovici T, Jha LK, Johnson T, et al. Systematic review: the relationship between interstitial lung diseases and gastro-oesoph-ageal reflux disease. Aliment Pharmacol Ther. 2011;34(11-12): 1295-1305.
31. Lock G, Pfeifer M, Straub RH, et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol. 1998;93(3):341-345.
32. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45(4):346-354.
33. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med. 1994;121(1):6-10.
34. McNearney TA, Sallam HS, Hunnicutt SE, et al. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol Motil. 2009;21(12):1269-e120.
35. Marie I, Levesque H, Ducrotté P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96(1):77-83.
36. Ariyasu H, Iwakura H, Yukawa N, et al. Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. Endocr J. 2014;61(7):735-742.
37. Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987;93(2):311-315.
38. Marie I, Antonietti M, Houivet E, et al. Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. Aliment Pharmacol Ther. 2014;40(2):189-199.
39. Ghrénassia E, Avouac J, Khanna D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol. 2014;41(1):99-105.
40. Fynne L, Worsøe J, Gregersen T, Schlageter V, Laurberg S, Krogh K. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011;46(10):1187-1193.
41. Marie I, Ducrotté P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis—a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007;46(1):150-153.
42. Sjölund K, Bartosik I, Lindberg G, Scheja A, Wildt M, Akesson A. Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol. 2005;17(11):1205-1212.
43. Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008;103(5): 1257-1262.
44. Amzallag-Bellenger E, Oudjit A, Ruiz A, Cadiot G, Soyer PA, Hoeffel CC. Effectiveness of MR enterography for the assessment of small-bowel diseases beyond Crohn disease. Radiographics. 2012;32(5):1423-1444.
45. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13(3):119-123.
46. Owyang C. Octreotide in gastrointestinal motility disorders. Gut. 1994;35(3)(Suppl):S11-S14.
47. Ritchie M, Caravelli J, Shike M. Benign persistent pneumoperitoneum in scleroderma. Dig Dis Sci. 1986;31(5):552-555.
48. London NJ, Bailey RG, Hall AW. Spontaneous benign pneumoperitoneum complicating scleroderma in the absence of pneumatosis cystoides intestinalis. Postgrad Med J. 1990;66(771): 61-62.
49. Kudoh K, Shibata C, Funayama Y, et al. Gastrojejunostomy and duodenojejunostomy for megaduodenum in systemic sclerosis sine scleroderma: report of a case. Dig Dis Sci. 2007;52(9):2257-2260.
50. Marie I, Ducrotté P, Denis P, Menard JF, Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009;48(10):1314-1319.
51. Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015;14(6):547-554.
52. Tauber M, Avouac J, Benahmed A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32(6)(Suppl 86):S-82-S-87.
53. Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol. 1995;34(3):265-269.
54. Braun-Moscovici Y, Braun M, Khanna D, Balbir-Gurman A, Furst DE. What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? Clin Exp Rheumatol. 2015;33(4)(Suppl 91):S117-S122.
55. Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol. 2011;29(2)(Suppl 65):S22-S25.
56. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461-1467.
57. Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS ONE. 2015;10(5):e0124205.
58. Wang SJ, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Colonic transit disorders in systemic sclerosis. Clin Rheumatol. 2001;20(4):251-254.
59. Govoni M, Muccinelli M, Panicali P, et al. Colon involvement in systemic sclerosis: clinical-radiological correlations. Clin Rheumatol. 1996;15(3):271-276.
60. Ackerman Z, Lysy J, Meiner-Lavie V. The association of fecal impaction and verapamil in a patient with scleroderma. Am J Gastroenterol. 1989;84(8):981-982.
61. Giuggioli D, Manfredi A, Colaci M, Ferri C. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers. Pain Med. 2010;11(10):1500-1503.
62. Thayalasekeran S, Ali H, Tsai HH. Novel therapies for constipation. World J Gastroenterol. 2013;19(45):8247-8251.
63. Wang SJ, Lan JL, Lan JL, et al. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21(4):271-274.
64. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97(1):194-197.
65. Valle RG, Godoy FL. Neostigmine for acute colonic pseudoobstruction: A meta-analysis. Ann Med Surg (Lond). 2014;3(3): 60-64.
66. Shamberger RC, Crawford JL, Kirkham SE. Progressive systemic sclerosis resulting in megacolon. A case report. JAMA. 1983;250(8):1063-1065.
67. Lindsey I, Farmer CR, Cunningham IG. Subtotal colectomy and cecosigmoid anastomosis for colonic systemic sclerosis: report of a case and review of the literature. Dis Colon Rectum. 2003;46(12):1706-1711.
68. Exadaktylos A, Papagrigoriadis S. Chronic constipation—a lethal danger in patients with systemic scleroderma. Eur J Emerg Med. 2001;8(4):333-335.
69. Sacher P, Buchmann P, Burger H. Stenosis of the large intestine complicating scleroderma and mimicking a sigmoid carcinoma. Dis Colon Rectum. 1983;26(5):347-348.
70. Budd DC, Nirdlinger EL, Sturtz DL, Fouty WJ Jr. Transverse colon volvulus associated with scleroderma. Am J Surg. 1977; 133(3):370-372.
71. Thoua NM, Schizas A, Forbes A, Denton CP, Emmanuel AV. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford). 2011;50(9):1596-1602.
72. Singh J, Mehendiratta V, Del Galdo F, et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1206-G1213.
73. Singh J, Cohen S, Mehendiratta V, et al. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology. 2012; 143(5):1308-1318.
74. Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S; M. Trezza, K. Krogh, H. Egekvist, P. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol. 1999;34(4):409-413.
75. Umar SB, Griffing L, Garcia H, Foxx-Orenstein AE, DiBaise JK, Crowell MD. The Impact of Pelvic Floor and Lower Gastrointestinal Symptoms on Quality of Life in Women With Systemic Sclerosis. J Clin Gastroenterol. 2015.
76. Heyt GJ, Oh MK, Alemzadeh N, et al. Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci. 2004;49(6):1040-1045.
77. Franck-Larsson K, Graf W, Eeg-Olofsson KE, Axelson HW, Rönnblom A. Physiological and structural anorectal abnormalities in patients with systemic sclerosis and fecal incontinence. Scand J Gastroenterol. 2014;49(9):1076-1083.
78. Fynne L, Luft F, Gregersen H, et al. Distensibility of the anal canal in patients with systemic sclerosis: a study with the functional lumen imaging probe. Colorectal Dis. 2013;15(1):e40-e47.
79. Jaffin BW, Chang P, Spiera H. Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol. 1997;25(3): 513-517.
80. Sallam HS, McNearney TA, Chen JZ. Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study. ISRN Gastroenterol. 2011;2011:402583.
81. deSouza NM, Williams AD, Gilderdale DJ. High-resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal receiver coil. Eur Radiol. 1999;9(3): 436-443.
82. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002;51(6):881-883.
83. Butt SK, Alam A, Cohen R, Krogh K, Buntzen S, Emmanuel A. Lack of effect of sacral nerve stimulation for incontinence in patients with systemic sclerosis. Colorectal Dis. 2015;17(10): 903-907.
84. Leighton JA, Valdovinos MA, Pemberton JH, Rath DM, Camilleri M. Anorectal dysfunction and rectal prolapse in progressive systemic sclerosis. Dis Colon Rectum. 1993;36(2): 182-185.
85. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257-1263.
86. Khanna D, Furst DE, Maranian P, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol. 2011;38(9): 1920-1924.